New Trial: Continuation Protocol for ZEN003694 in mCRPC Patients

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

New Trial: Continuation Protocol for ZEN003694 in mCRPC Patients

posted on Oct 30, 2019 11:17AM

Just posted on ClinicalTrials.gov! New continuation trial to allow for those experiencing benefit with ZEN-3694 + enzalutamide for mCRPC to continue for another 3 years!

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol